1.84
price up icon0.00%   0.00
after-market アフターアワーズ: 1.86 0.02 +1.09%
loading
前日終値:
$1.84
開ける:
$1.8385
24時間の取引高:
802.17K
Relative Volume:
0.27
時価総額:
$183.59M
収益:
-
当期純損益:
$-37.34M
株価収益率:
-1.3529
EPS:
-1.36
ネットキャッシュフロー:
$-36.91M
1週間 パフォーマンス:
-4.17%
1か月 パフォーマンス:
+7.60%
6か月 パフォーマンス:
+86.07%
1年 パフォーマンス:
+56.60%
1日の値動き範囲:
Value
$1.82
$1.855
1週間の範囲:
Value
$1.76
$1.94
52週間の値動き範囲:
Value
$0.772
$2.2691

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Name
名前
Sellas Life Sciences Group Inc
Name
セクター
Healthcare (1163)
Name
電話
(646) 200-5278
Name
住所
7 TIMES SQUARE, NEW YORK, NY
Name
職員
15
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
SLS's Discussions on Twitter

SLS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SLS
Sellas Life Sciences Group Inc
1.84 183.59M 0 -37.34M -36.91M -1.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2021-07-21 開始されました Cantor Fitzgerald Overweight
2018-11-01 開始されました Oppenheimer Outperform
2018-04-02 開始されました H.C. Wainwright Buy
2018-03-19 アップグレード Maxim Group Hold → Buy

Sellas Life Sciences Group Inc (SLS) 最新ニュース

pulisher
Jul 22, 2025

What analysts say about SELLAS Life Sciences Group Inc. stockDynamic capital growth - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

What drives SELLAS Life Sciences Group Inc. stock priceFree Stock Index Interpretation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is SELLAS Life Sciences Group Inc. a good long term investmentFree Bull & Bear Market Updates - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

SELLAS Life Sciences Group Inc. Stock Analysis and ForecastFree Advanced Stock Screener Access - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

What makes SELLAS Life Sciences Group Inc. stock attractive to long term investorsMomentum Swing Watchlist - beatles.ru

Jul 20, 2025
pulisher
Jul 18, 2025

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Expected to Rise, Maxim Group Analyst Says - Defense World

Jul 18, 2025
pulisher
Jul 16, 2025

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities - Finansavisen

Jul 16, 2025
pulisher
Jul 16, 2025

Sellas Life Sciences shares fall 1.58% premarket after meeting primary endpoints in Phase 2 trial. - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

SELLAS Meets All Primary Endpoints in Phase 2 Trial of - GlobeNewswire

Jul 16, 2025
pulisher
Jul 15, 2025

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success - insights.citeline.com

Jul 15, 2025
pulisher
Jul 15, 2025

What makes SELLAS Life Sciences Group Inc. stock price move sharplyReal Time Breakout Tracking - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How SELLAS Life Sciences Group Inc. stock performs during market volatilityHigh Yield Opportunities - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Sellas Flat on Trial Success - Baystreet.ca

Jul 15, 2025
pulisher
Jul 15, 2025

Sellas Life Sciences Meets Primary Endpoints in Mid-Stage SLS009 Trial - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

SELLAS gains on mid-stage trial win for leukemia drug (SLS) - Seeking Alpha

Jul 15, 2025
pulisher
Jul 15, 2025

SELLAS' Phase 2 Study Of SLS009 In Acute Myeloid Leukemia Meets All Primary Goals - Nasdaq

Jul 15, 2025
pulisher
Jul 15, 2025

Why SELLAS Life Sciences Group Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

SELLAS Life Sciences Group Reports Positive Phase 2 Trial Results for SLS009 in Relapsed/Refractory Acute Myeloid Leukemia - Nasdaq

Jul 15, 2025
pulisher
Jul 15, 2025

SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study - The Manila Times

Jul 15, 2025
pulisher
Jul 10, 2025

SELLAS Life Sciences Soars 14.21% on Key Appointment - AInvest

Jul 10, 2025
pulisher
Jul 09, 2025

SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Market Movement, Down and Up - investchronicle.com

Jul 09, 2025
pulisher
Jul 09, 2025

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 3.7% – Here’s What Happened - Defense World

Jul 09, 2025
pulisher
Jul 07, 2025

SELLAS Life Sciences adds cancer research expert to scientific board By Investing.com - Investing.com Nigeria

Jul 07, 2025
pulisher
Jul 07, 2025

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board - citybiz

Jul 07, 2025
pulisher
Jul 07, 2025

SELLAS Life Sciences adds cancer research expert to scientific board - Investing.com

Jul 07, 2025
pulisher
Jul 07, 2025

Cancer Research Leader from MD Anderson Strengthens SELLAS Scientific Board Ahead of Key Milestones - Stock Titan

Jul 07, 2025
pulisher
Jun 30, 2025

SELLAS Life Sciences Group, Inc.(NasdaqCM: SLS) added to Russell 2500 Growth Index - MarketScreener

Jun 30, 2025

Sellas Life Sciences Group Inc (SLS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
大文字化:     |  ボリューム (24 時間):